Marixino 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0015 
Minor change in labelling or package leaflet not 
06/12/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0014 
C.I.z - Changes (Safety/Efficacy) of Human and 
06/11/2020 
18/11/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
T/0013 
Transfer of Marketing Authorisation 
16/03/2018 
04/04/2018 
SmPC, 
and PL 
Labelling and 
PL 
R/0012 
Renewal of the marketing authorisation. 
12/10/2017 
18/01/2018 
SmPC, 
Labelling and 
PL 
IA/0011/G 
This was an application for a group of variations. 
29/06/2017 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IB/0010 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
05/04/2017 
18/01/2018 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0009 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
03/03/2017 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0008 
C.I.z - Changes (Safety/Efficacy) of Human and 
11/05/2016 
16/06/2017 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
IAIN/0007 
C.I.8.a - Introduction of or changes to a summary of 
11/08/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0006 
B.II.b.1.a - Replacement or addition of a 
02/02/2015 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
N/0005 
Minor change in labelling or package leaflet not 
19/01/2015 
16/06/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0004 
B.I.a.3.a - Change in batch size (including batch size 
24/10/2013 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IAIN/0003 
A.2.a - Administrative change - Change in the 
09/08/2013 
26/08/2014 
SmPC, 
(invented) name of the medicinal product for CAPs 
Labelling and 
PL 
T/0002 
Transfer of MA from Krka d.d. Novo mesto to 
08/07/2013 
05/08/2013 
SmPC, 
Consilient Health Ltd 
Transfer of Marketing Authorisation 
Labelling and 
PL 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
